Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

, regulatory filings and actions and Onyx's anticipated acquisition of Proteolix, Inc. and its lead product candidate, carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; competition; failures or delays in our clinical trials; dependence on our collaborative relationship with Bayer; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; product liability risks; and the consummation and anticipated benefits of the proposed acquisition of Proteolix. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of these and other risks, as well as the company's subsequent quarterly reports on Form 10Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

                           (See attached tables.)


                        ONYX PHARMACEUTICALS, INC.
                    CONDENSED STATEMENTS OF OPERATIONS
                 (In thousands, except per share amounts)
                                (unaudited)

                    
'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... San Francisco, CA (PRWEB) , ... August 03, 2015 , ... ... MSHA, as the chief operating officer (COO) at CPMC. Hamila will start in her ... four hospital campuses. , Kownacki has worked at CPMC and Sutter Health for ...
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... 03, 2015 , ... They know every second counts. And when it comes ... some of the best care in the nation. For the past two months, the ... blood clot removal time in the country. During the months of June and July, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
Breaking Medicine News(10 mins):Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Human Resources continues to,be a big cost center, ... cost reductions and productivity improvements. So how can ... comprehensive HR metrics study by benchmarking leader Best Practices,LLC ... of performance,metrics for your key HR functions: Staffing, Benefits, ...
... Just six hours of instruction improved relationships with patients, ... -- New evidence suggests that a bit of theatrics ... is based on the experience of a small group ... of theater workshops and lectures led by university theater ...
... Today in Major Indian Newspapers Includes, Chart Comparing Cipla ... ... India, Sept. 6 As part of its,ongoing global campaign to ... Healthcare Foundation (AHF),has published a print advertisement in the form of ...
... forward,to Saturday, September 8,s Michigan Policy Summit as a ... education, women,s and,civil rights, labor and social justice organizations ... a common action agenda around the,issues of education, energy ... hangs in the balance," stated AFT Michigan,President David Hecker. ...
... Prime Therapeutics (Prime), a,thought leader in ... in Pharmaceutical Purchasing Standards SM (TIPPS SM),certification. ... the HR Policy Association,Pharmaceutical Coalition, an alliance ... initiative calls for adherence to nine drug ...
... Sept. 6 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ... its 2006 Annual Report on Form 10-K. The,filing of ... to the work,involved in restating its consolidated financial statements ... Par intends to file its,Form 10-Q for the first ...
Cached Medicine News:Health News:End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 2Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 3Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 4Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 5Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 6Health News:'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign 7Health News:Prime Therapeutics Receives TIPPS Certification 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12
(Date:8/3/2015)... , August 3, 2015 ... between biotech companies, military surgical research and ... therapies with regards to severe wound treatments ... enhancements for regenerative medicine and tissue-engineered skin ... partnerships and advancements in focus are Amarantus ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 27, 2011 Reportlinker.com announces that ... available in its catalogue: ... Market Outlook to 2017- Glucose Monitoring ... http://www.reportlinker.com/p0739472/United-States-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology United ...
... December 27, 2011 ReportsnReports adds ... in Latin America , to its store. This ... in terms of their attractiveness as pharmaceutical markets ... property, and pricing are examined. The report presents ...
Cached Medicine Technology:United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 10United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 11United States Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 12Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 2Latin America Emerging Pharmaceutical Markets - Argentina, Chile, Colombia, Peru, and Venezuela 3